No significant differences in recurrence rates among women with DCIS taking anastrozole or tamoxifen
Sunday, December 13, 2015 - 17:11
in Health & Medicine
Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two groups had different side effects.